Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI

Related Keywords

United States ,Israel ,America ,Jo Anne Goldman ,Deepakl Bhatt ,Stephena Hill ,Steering Committee ,Minneapolis Heart Institute Foundation In ,Women Health ,Faraday Pharmaceuticals Inc ,Drug Administration ,Professor Of Medicine At Harvard Medical School ,Faraday Pharmaceuticals ,Special Protocol Agreement ,Jay Traverse ,Minneapolis Heart Institute Foundation ,Executive Director ,Interventional Cardiovascular Programs ,Harvard Medical School ,North America ,